Greenwich LifeSciences (NASDAQ:GLSI) Shares Gap Down to $45.16

Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) gapped down before the market opened on Friday . The stock had previously closed at $45.16, but opened at $42.70. Greenwich LifeSciences shares last traded at $42.58, with a volume of 1,118 shares.

Separately, HC Wainwright initiated coverage on Greenwich LifeSciences in a research report on Wednesday, September 1st. They issued a “buy” rating and a $78.00 target price on the stock.

The stock’s 50 day moving average is $41.77 and its two-hundred day moving average is $38.77.

A number of institutional investors have recently bought and sold shares of GLSI. Invesco Ltd. purchased a new position in Greenwich LifeSciences in the 2nd quarter valued at approximately $12,586,000. BlackRock Inc. lifted its position in Greenwich LifeSciences by 242.7% in the second quarter. BlackRock Inc. now owns 217,748 shares of the company’s stock valued at $9,786,000 after acquiring an additional 154,208 shares during the last quarter. Vanguard Group Inc. lifted its position in Greenwich LifeSciences by 14.3% in the second quarter. Vanguard Group Inc. now owns 121,418 shares of the company’s stock valued at $5,457,000 after acquiring an additional 15,157 shares during the last quarter. Geode Capital Management LLC lifted its position in Greenwich LifeSciences by 262.3% in the second quarter. Geode Capital Management LLC now owns 52,395 shares of the company’s stock valued at $2,354,000 after acquiring an additional 37,932 shares during the last quarter. Finally, State Street Corp acquired a new position in Greenwich LifeSciences in the second quarter valued at $2,257,000. Hedge funds and other institutional investors own 6.26% of the company’s stock.

Greenwich LifeSciences Company Profile (NASDAQ:GLSI)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery.

See Also: Why are percentage gainers important?

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.